The research included a study about Aryl esterase enzyme in (60) serum samples of patients with atherosclerosis whose ages ranged between 25 to 75 years and compared it with (60) serum samples of the control group whose ages ranged between 25 to 60 years in Tikrit City from November 2022 to February 2023. The results showed a highly significant decrease (P ≤ 0.005) in the serum levels of aryl esterase of patients with atherosclerosis (71.2 ± 3.7 U/L) compared to the control group (135.36 ± 1.7 U/L). The result also demonstrated no variation due to sex but a decline with age progress. A significant decrease was observed in the activity of aryl esterase and the level of high-density lipoprotein (HDL), and a significant increase in the level of troponin T(TnT), total cholesterol(TCH), triglycerides (TG), very low-density lipoprotein (vLDL), and low-density lipoprotein (LDL) in the serum of patients compared to the control group. The relationship between the activity of the enzyme and many clinical variables was studied in both groups by finding the linear correlation coefficient, as it was found that HDL was associated with the activity of the enzyme with a direct relationship in the group of patients.
Copyright © 2020 All rights reserved | Bulletin of National Institute of Health Sciences